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Edited by Dr Gabrielle Prager on behalf of the RCEM COVID-19 CPD team 
Following from the successful "RCEM weekly top five" series starting in April 2020, this is 
the third of a monthly format for EMJ readers. We have undertaken a focussed search of 
the PubMed literature using a standardised COVID-19 search string. Our search between 
1st December and 31st December 2020 returned 1183 papers limited to human subjects and 
English language. We also searched high impact journals for papers of interest. 
Our team have narrowed down the most interesting, relevant and important of the papers 
and provided a critical snapshot of 5 of those we felt most deserved EMJ reader attention. 
Importantly, we have highlighted not only the main findings from the papers but key 
limitations and considerations for EM clinicians when interpreting the work. In doing so have 
created an accessible window into pertinent research findings for our busy colleagues during 
this fast-paced and ever-changing COVID-19 landscape.  
The papers are ranked in one of 3 categories, allowing you to focus on the papers that are 
most vital to your practice:  
 Worth a peek - interesting, but not yet ready for prime time  
 Head turner - new concepts  
 Game changer - this paper could/should change practice  
This month's searches were undertaken by the Centre for Urgent and Emergency Care 
Research at the University of Sheffield.  We look forward to next month's instalment by our 





1. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results 
(1) 
Topic:   Treatment  
Outcome Rating:  Game Changer 
In March 2020, the World Health Organisation (WHO) recommended randomised trials into 
potential treatments for COVID-19. Experts agreed on four antiviral drugs that could be 
repurposed to reduce mortality in this patient group.  The four drugs were remdesivir, 
hydroxychloroquine, lopinavir and interferon beta-1a.   
Within a month a large international, open-label randomised trial was launched at 405 
hospitals in 30 different countries.  There was no placebo group; the control group consisted 
of the local usual care.  Adult patients (>18) who were hospitalised with COVID-19 and not 
currently on a trial drug were included.  The primary outcome was in-hospital mortality with 
the secondary outcomes being the length of stay and requirement for mechanical ventilation.  
The protocol specified a sub-group analysis of severe COVID-19 but did not define “severe”, 
so sub-group analysis is limited.  The trial was adaptive, dropping ineffective treatments and 
adding other potential candidate drugs.  Hydroxychloroquine was dropped after three 
months, lopinavir after four, and interferon after seven months.  The trial is still recruiting 
and has since included monoclonal antibodies into the protocol.  At the time of this interim 
publication the study had recruited 11,266 patients into the intention-to-treat analysis.  There 
were 954 patients randomised to hydroxychloroquine, and the rate ratio for in-hospital 
mortality was 1.19 (0.89-1.59) vs control. There were 1411 patients randomised to lopinavir, 
which had a rate ratio of 1.00 (0.75-1.25) vs. control. There were 2063 randomised to 
interferon which had a rate ratio of 1.16 (0.96-1.39).  There have been 2750 assigned to 
remdesivir so far, and this interim analysis shows a rate ratio of 0.95 (95% CI 0.81-1.11) vs 
control. 
The sub-group analysis and secondary outcomes also failed to demonstrate a reduction 
using these repurposed antivirals.  The trial has been criticised for its open design and the 
heterogeneity of the population and control treatments, but it is difficult to see how the former 
could influence mortality.   Furthermore, the latter could be considered a strength if it 




Bottom line: This was a large, well-conducted trial which has shown that previously 
developed antivirals do not significantly reduce mortality, length of stay, or the requirement 




2. A systematic review of corticosteroid treatment for non-critically ill patients 
with COVID-19 (2) 
Topic:   Treatment 
Outcome Rating:  Head-turner 
Between July and September 2020, strong and widely-implemented evidence emerged 
that corticosteroids reduce mortality in patients with 'severe' and 'critical' COVID-19.  This 
evidence is largely based on a systematic review and meta-analysis of seven trials, of 
which the RECOVERY trial was the largest (3,4).   Conversely, the evidence for 
corticosteroids’ lack of effect in non-severe and non-critical COVID-19 is based on the 
results of the RECOVERY trial alone (4).  This paper sought to redress the balance by 
systematically reviewing controlled observational studies in addition to RCTs to broaden 
the evidence base for corticosteroids in non-critical COVID-19.   
PRISMA guidelines were followed throughout. 'Non-critical' was defined as COVID-19 not 
requiring mechanical ventilation.  Five observational studies and the RECOVERY trial 
were included.  The observational studies used propensity matching but remained at risk 
of bias due to retrospective design, heterogeneous interventions (corticosteroid choice, 
dose and timing) and lack of placebo.  Study heterogeneity precluded meta-analysis.  It is 
worth noting that RECOVERY was by far the largest single study (n = 5,418) and that the 
observational studies only contributed a total of 480 patients. 
Two of the observational studies assessed in-hospital mortality, one in severe (non-critical) 
cases, and the other in moderate cases.  Neither found an association between 
corticosteroids and in-hospital mortality, which is concordant with the findings of 
RECOVERY and aligns with WHO guidance which does not advocate corticosteroids in 
non-severe COVID-19.  Four of the additional studies assessed secondary outcomes such 
as duration of hospitalisation, length of viral shedding and disease progression, with mixed 
results.   
Bottom line: the available evidence suggests that there is no mortality benefit from 
corticosteroids in non-severe and non-critical COVID-19.  
 
 
3. Obesity is associated with increased severity of disease in COVID-19 
pneumonia: a systematic review and meta-analysis (5) 
Topic:   Epidemiology 
Outcome Rating:  Worth a peek 
A higher prevalence of obesity in younger Western patients may mean that COVID-19 will 
cause more severe disease in a greater number of younger patients than has previously 
been reported (6). 
This systematic review and meta-analysis looked at the association between body mass 
index or obesity and outcomes in COVID-19.  Twenty-two studies comprising 12,591 
patients were included.  The meta-analysis demonstrated that obesity was not associated 
with increased mortality.  However, obesity was associated with a range of other adverse 
outcomes including disease progression (OR 1.41, 95% CI 1.26-1.58), severe COVID-19 
(OR 4.17, 95% CI 2.32-7.48), intensive care admission (OR 1.57, 95% CI 1.19-2.09) and 
mechanical ventilation (OR 2.13, 95% CI 1.10-4.14).  The association between obesity and 
poor outcomes was more pronounced for younger patients (aged <60 years) than older 
patients. 
The authors note that the complex relationship between obesity and mortality has been 
observed in previous studies of pneumonia, but also draw attention to the fact that 
heterogeneity in their included studies may under-estimate the mortality in obese patients.  
The most important additional limitations include: varying definitions of obesity used by 
included studies (28-30kg/m2), the reliance of studies on estimated or patient-reported 
data, and the lack of sufficient data to perform an analysis on overweight (as opposed to 
obese) patients.  Nonetheless, the increased severity of disease in obese young patients 
may have significant implications for healthcare systems treating populations in which 
obesity is prevalent among younger patients.   
Bottom line: emergency physicians should consider obesity a risk factor for severe illness 




4. Decontamination of N95 masks for re-use employing 7 widely available 
sterilization methods (7)  
Topic:   Personal Protective Equipment  
Outcome Rating:    Head turner  
Healthcare providers around the world continue to face a shortage of personal protective 
equipment (PPE), including N95 respirator masks, which offer protection for respiratory 
viruses such as SARS-CoV-2.  The standard manufacturers' recommendation is that N95 
masks are single-use products. However, developing safe and effective methods to 
decontaminate the masks has the potential to enable re-use and reduce shortages. 
In this study the authors experimentally contaminated four different mask models with 
SARS-CoV-2 and assessed several decontamination methods.  The mask models were: 
VFlex 1804, Aura 1870, 1860 (The 3M Company, St Paul, Minnesota) and AO Safety 
1054S (Pleats Plus) Respirator (Aearo Technologies, Indianapolis).  The methods of 
decontamination were: autoclave treatment, vaporous hydrogen peroxide exposure, 
peracetic acid dry fogging, ultraviolet C radiation and moist heat.  The authors also 
evaluated the number of decontamination cycles that the masks could tolerate without 
affecting their structural and functional integrity.  This was achieved through quantitative fit 
testing and laboratory particulate filtration testing. 
All the decontamination methods except ultraviolet C radiation were effective in sterilising 
the masks without affecting the structure and functional integrity for at least one cycle.  
Autoclave treatment was effective in all models for at least one cycle, and in some models 
for up to 10 cycles.  Finally, three of the effective methods (vaporous hydrogen peroxide, 
peracetic acid dry fogging and moist heat treatment) were associated with both fit and 
filtration integrity in all mask models up to at least ten cycles.  
This study provides evidence on decontamination practices for N95 masks when it is not 
possible to follow the ideal single use recommendation for each patient encounter. The 
authors emphasise that since access to autoclaves is ‘near universal’ the findings may be 
highly relevant in resource-poor settings where PPE procurement remains a daily problem. 
Bottom line: emergency physicians facing resource shortages should be aware of the 





5. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (8) 
Topic:   Prevention  
Outcome Rating:  Game changer 
The development of candidate vaccines against COVID-19 has been an unprecedented 
scientific effort, and the subsequent demonstration of their efficacy is a landmark moment in 
the course of the pandemic.  The Pfizer/BioNTech mRNA vaccine was the first to complete 
phase 3 trials, publish its results and become licensed for use in the UK. 
The authors conducted a randomised, placebo-controlled, observer-blinded multinational 
trial. Adults >16 years who were either healthy or had stable chronic health conditions 
received two intramuscular injections of BNT162b2, or an equivalent volume of saline, 21 
days apart.  Patients were excluded if they had a history of COVID-19 or if they were 
immunosuppressed.  Safety assessment was conducted through solicited and unsolicited 
methods and will continue up to 2 years after the second dose was administered (although 
only safety up to 14 weeks is included in this paper).  
44,820 participants were randomised of whom 21,720 received the candidate vaccine.  
Adverse reactions were reported 21% of vaccinated participants compared to 5% of placebo 
recipients.  Almost all reactions were mild or moderate local or systemic reactions such as 
pain at injection site, headache or fatigue.  There were four serious related adverse events 
in vaccinated participants: a shoulder injury related to vaccine administration, right axillary 
lymphadenopathy, paroxysmal ventricular arrhythmia and right leg paraesthesia.  There 
were no related deaths in either the vaccine or placebo group.   
The trial assessed efficacy by comparing the rates of illness from COVID-19 in the 
vaccinated and placebo groups.  Between the first and the second dose there were 39 cases 
of symptomatic COVID-19 in the vaccination group compared to 82 cases in the placebo 
group, yielding an overall efficacy of 52% (95% CI 29.5 - 68.4).  Among patients who had 
two doses, there were 8 cases of COVID-19 which occurred at least 7 days after the second 
dose in the vaccination group compared to 162 cases in the placebo group, yielding a 
vaccine efficacy of 95% (95% CI 90.3 - 97.6) by 12 days after the second dose. 
There are some important limitations to consider. The study did not routinely test people for 
COVID-19; they only tested people if they became symptomatic. In other words, they could 
not say if people had asymptomatic disease in the vaccine group. As a result, it is currently 
 
 
unknown whether someone with the vaccine can acquire COVID-19 and transmit it to others, 
even if the person vaccinated remains asymptomatic. For this reason, people fully 
vaccinated are still asked to quarantine if they become a close contact to someone with 
COVID-19. 
In addition, no data are reported on the efficacy of a single dose of vaccine beyond 21 days 
after administration, and nor are there any data on the efficacy of two doses delivered more 
than 21 days apart.  
Finally, 82.9% of participants were white, the median age was 52 years with 42% of 
participants over 55 years, and 130 of the 152 trial sites were in the USA.   Exclusion criteria 
have left some questions about how the vaccines will work in those previously infected by 
COVID-19 or immunosuppressed.  
Bottom line: emergency physicians can be confident that the Pfizer/BioNTech vaccine is 
safe and effective in preventing illness but should remain alert to how these findings translate 
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